ArticleEuropean cells & materials2014
Time and dose-dependent effects of chondroitinase ABC on growth of engineered cartilage.
Article in European cells & materials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Bioassembly of Region-Specific Fibrocartilage Microtissues to Engineer Zonally Defined Meniscal Grafts.Advanced healthcare materials · 2025Article
- An Ex Vivo Model of Intervertebral Disc Degeneration for Assessing Retention of Injectable Cell-Based Grafts.JOR spine · 2025Article
- Effect of Passaging on Bovine Chondrocyte Gene Expression and Engineered Cartilage Production.Tissue engineering. Part A · 2024Article
- Addition of collagen type I in agarose created a dose-dependent effect on matrix production in engineered cartilage.Regenerative biomaterials · 2022Article
- Proteoglycan-depleted regions of annular injury promote nerve ingrowth in a rabbit disc degeneration model.Open medicine (Warsaw, Poland) · 2021Article
- A modular approach to creating large engineered cartilage surfaces.Journal of biomechanics · 2018Article
- Article
- Human chondrocyte migration behaviour to guide the development of engineered cartilage.Journal of tissue engineering and regenerative medicine · 2017Article
- High fidelity visualization of cell-to-cell variation and temporal dynamics in nascent extracellular matrix formation.Scientific reports · 2016Article
- High seeding density of human chondrocytes in agarose produces tissue-engineered cartilage approaching native mechanical and biochemical properties.Journal of biomechanics · 2016Article
- A puzzle assembly strategy for fabrication of large engineered cartilage tissue constructs.Journal of biomechanics · 2016Article
- Articular cartilage tissue engineering: the role of signaling molecules.Cellular and molecular life sciences : CMLS · 2016Review
- Continuum theory of fibrous tissue damage mechanics using bond kinetics: application to cartilage tissue engineering.Interface focus · 2016Article
- Mesenchymal Stem Cells for Osteochondral Tissue Engineering.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Pediatric laryngotracheal reconstruction with tissue-engineered cartilage in a rabbit model.The Laryngoscope · 2016Article
- Matrix Production in Large Engineered Cartilage Constructs Is Enhanced by Nutrient Channels and Excess Media Supply.Tissue engineering. Part C, Methods · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Tissue engineering techniques have been effective in developing cartilage-like tissues in vitro. However, many scaffold-based approaches to cultivating engineered cartilage have been limited by low collagen production, an impediment for attaining native functional load-bearing tensile mechanical properties. Enzymatic digestion of glycosaminoglycans (GAG) with chondroitinase ABC (chABC) temporarily suppresses the construct's GAG content and compressive modulus and increases collagen content. Based on the promising results of these early studies, the aim of this study was to further promote collagen deposition through more frequent chABC treatments. Weekly dosing of chABC at a concentration of 0.15 U/mL resulted in a significant cell death, which impacted the ability of the engineered cartilage to fully recover GAG and compressive mechanical properties. In light of these findings, the influence of lower chABC dosage on engineered tissue (0.004 and 0.015 U/mL) over a longer duration (one week) was investigated. Treatment with 0.004 U/mL reduced cell death, decreased the recovery time needed to achieve native compressive mechanical properties and GAG content, and resulted in a collagen content that was 65 % greater than the control. In conclusion, the results of this study demonstrate that longer chABC treatment (one week) at low concentrations can be used to improve collagen content in developing engineered cartilage more expediently than standard chABC treatments of higher chABC doses administered over brief durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.